How to treat anemia in the myelodysplastic syndrome (MDS) is controversial. Many health care systems refuse to fund erythropoietin on grounds of health economics. A new paper on the effect of anemia in MDS on cardiac remodeling has suggested that a higher treatment threshold level for hemoglobin should be introduced. This would have an impact of the calculation of risk/benefits.